Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer

Journal of Pathology

Volumn 227, Issue 1, 2012, Pages 53-61

  Wu, Chunxiao ^a   Wyatt, Alexander W ^a   Lapuk, Anna V ^a   McPherson, Andrew ^b,c   McConeghy, Brian J ^a   Bell, Robert H ^a   Anderson, Shawn ^a   Haegert, Anne ^a   Brahmbhatt, Sonal ^a   Shukin, Robert ^a   Mo, Fan ^a   Li, Estelle ^a   Fazli, Ladan ^a   Hurtado Coll, Antonio ^a   Jones, Edward C ^a   Butterfield, Yaron S ^b   Hach, Faraz ^c   Hormozdiari, Fereydoun ^c   Hajirasouliha, Iman ^c   Boutros, Paul C ^d   Bristow, Robert G ^d   Jones, Steven J M ^b   Hirst, Martin ^b   Marra, Marco A ^b   Maher, Christopher A ^e   Chinnaiyan, Arul M ^e   Sahinalp, S Cenk ^c   Gleave, Martin E ^a   Volik, Stanislav V ^a   Collins, Colin C ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cancer genetics; DNA sequencing; Fusion genes; Neuroendocrine; Personalized medicine; Prostate cancer; RNA sequencing

Indexed keywords

BICALUTAMIDE; GENOMIC DNA; GONADORELIN DERIVATIVE; RNA; TRANSCRIPTOME;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER HORMONE THERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CELL TYPE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; FUSION GENE; GENE EXPRESSION; GENOME; HUMAN; HUMAN TISSUE; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE;

EID: 84975810758     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3987     Document Type: Article

References (53)

1. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331: 1553-1558.
2. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. J Am Med Assoc 2011; 305: 1568-1576.
3. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. J Am Med Assoc 2011; 305: 1577-1584.
4. Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostat Dis 2004; 7: 188-194. (Pubitemid 41741501)
5. Long RM, Morrissey C, Fitzpatrick JM, et al. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005; 108: 1-11. (Pubitemid 40052280)
6. Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011; 30: 1261-1271.
7. Leong KG, Wang BE, Johnson L, et al. Generation of a prostate from a single adult stem cell. Nature 2008; 456: 804-808.
8. Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-571.
9. Cindolo L, Cantile M, Vacherot F, et al. Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int 2007; 79: 287-296. (Pubitemid 350136512)
10. Nelson EC, Cambio AJ, Yang JC, et al. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostat Dis 2007; 10: 6-14. (Pubitemid 46358906)
11. Wang J, Kim J, Roh M, et al. Pim1 kinase synergizes with c- MYC to induce advanced prostate carcinoma. Oncogene 2010; 29: 2477-2487.
12. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-547. (Pubitemid 350074046)
13. Cox ME, Deeble PD, Lakhani S, et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999; 59: 3821-3830. (Pubitemid 29381892)
14. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 2011; 24: 1120-1127.
15. Makarenkov V. T-REX: reconstructing and visualizing phylogenetic trees and reticulation networks. Bioinformatics 2001; 17: 664-668.
16. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
17. Li H, Ruan J, Durbin R. Mapping short DNA sequencing reads and calling variants using mapping quality scores. Genome Res 2008; 18: 1851-1858.
18. McPherson A, Hormozdiari F, Zayed A, et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 2011; 7: e1001138.
19. McPherson A, Wu C, Hajirasouliha I, et al. Comrad: a novel algorithmic framework for the integrated analysis of RNA-Seq and WGSS data. Bioinformatics 2011; 27: 1481-1488.
20. Griffith M, Griffith OL, Mwenifumbo J, et al. Alternative expression analysis by RNA sequencing. Nat Methods 2010; 7: 843-847.
21. Lapuk A, Marr H, Jakkula L, et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 2010; 8: 961-974.
22. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
23. Yang J, Zhao YL, Wu ZQ, et al. The single-macro domain protein LRP16 is an essential cofactor of androgen receptor. Endocr Relat Cancer 2009; 16: 139-153.
24. Siddall NA, McLaughlin EA, Marriner NL, et al. The RNA-binding protein Musashi is required intrinsically to maintain stem cell identity. Proc Natl Acad Sci USA 2006; 103: 8402-8407. (Pubitemid 43838467)
25. Rubin CM, Carrino JJ, Dickler MN, et al. Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1988; 85: 2795-2799.
26. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
27. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29: 742-749.
28. Nacu S, Yuan W, Kan Z, et al. Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genomics 2011; 4: 11.
29. Kannan K, Wang L, Wang J, et al. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 2011; 108: 9172-9177.
30. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-592; discussion, 592.
31. Hu Y, Ippolito JE, Garabedian EM, et al. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002; 277: 44462-44474. (Pubitemid 36157881)
32. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
33. Gregg JL, Brown KE, Mintz EM, et al. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 2010; 10: 165.
34. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010; 41: 781-793.
35. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448: 595-599. (Pubitemid 47206938)
36. Berg A, Zelano J, Cullheim S. Netrin G-2 ligand mRNA is down-regulated in spinal motoneurons after sciatic nerve lesion. NeuroReport 2010; 21: 782-785.
37. Berkel S, Marshall CR, Weiss B, et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 2010; 42: 489-491.
38. Dong C, Yang L, Zhang X, et al. Rab8 interacts with distinct motifs in α2B- and β2-adrenergic receptors and differentially modulates their transport. J Biol Chem 2010; 285: 20369-20380.
39. Bralten LB, Gravendeel AM, Kloosterhof NK, et al. The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Oncogene 2010; 29: 6138-6148.
40. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326: 1230.
41. Bastus NC, Boyd LK, Mao X, et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70: 9544-9548.
42. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-1083.
43. Nambiar M, Raghavan SC. How does DNA break during chromosomal translocations? Nucleic Acids Res 2011; 39: 5813-5825.
44. Zhou Z, Flesken-Nikitin A, Nikitin AY. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 2007; 67: 5683-5690. (Pubitemid 46985000)
45. Chiaverotti T, Couto SS, Donjacour A, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172: 236-246. (Pubitemid 351186384)
46. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466: 765-768.
47. Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16: 903-908.
48. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
49. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29: 4080-4090.
50. Bloethner S, Mould A, Stark M, et al. Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay. Genes Chromosomes Cancer 2008; 47: 1076-1085.
51. Bourguignon LY, Singleton PA, Zhu H, et al. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem 2003; 278: 29420-29434. (Pubitemid 36962321)
52. Robbins CM, Tembe WA, Baker A, et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011; 21: 47-55.
53. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. Genome Res 2010; 20: 413-427.